Data from a Phase 1a/b study of mRNA encoding for vascular endothelial growth factor A (VEGF-A) shows tolerability, protein expression and protein pharmacology in human subjects and its potential for use as a regenerative therapeutic.
Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo
In vivo studies show that intradermal injection of mRNA encoding the VEGF-A protein results in rapid and local dose-dependent protein production, suggesting therapeutic potential in vascular conditions.
Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing
In mouse models, the intradermal administration of mRNA encoding for VEGF-A can induce a localized, sustained, and reproducible biological response, including blood vessel formation and oxygenation to accelerate diabetic wound healing.
Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine
Large animal studies demonstrate that direct injection of modified mRNA can produce local protein expression while maintaining immune silence, and can induce physiological effects at an organ level.
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction
This foundational paper establishes that direct injection of modified mRNA in mice can induce local physiological changes and could be an effective approach for regenerative therapeutics.